HEFEI, China, April 7, 2026 /PRNewswire/ — Sungrow’s commercial and industrial (C&I) energy storage system PowerKeeper has successfully completed cell, module, and unit-level thermal runaway tests under the UL 9540A standard, becoming the industry’s first modular DC-coupled C&I ESS to achieve triple-level certification. Witnessed by TÜV Rheinland, the testing validates PowerKeeper’s ability to effectively prevent thermal runaway propagation across multiple system layers—setting a new benchmark for safety in commercial and industrial energy storage.

Beyond Single-Level Testing: A New Approach to Energy Storage Safety

In commercial and industrial environments such as shopping malls, office buildings, hotels, and factories, energy storage systems are often installed in high-density spaces where people, equipment, and valuable assets coexist. Given these scenarios, safety requirements extend far beyond basic compliance. The fundamental challenge in battery safety is not simply responding to fire incidents, but preventing thermal runaway propagation before risks escalate.

UL 9540A is widely recognized as the global benchmark for evaluating thermal runaway risks in energy storage systems. However, current industry practice typically focuses on single-tier testing, either by validating cell-level parameters alone or by demonstrating compliance only at the module or system level. Such fragmented testing cannot fully demonstrate whether every safety barrier within a system can contain potential risks.

PowerKeeper addresses this challenge through a comprehensive triple-layer safety validation approach.

Building a Complete Safety Evidence Chain

Through its cell-module-unit triple UL 9540A certification, PowerKeeper establishes a complete safety validation chain across three system layers:

• Cell-level testing captures critical thermal runaway parameters.
• Module-level testing verifies that thermal runaway can be contained within the battery module.
• Unit-level testing demonstrates effective thermal isolation between adjacent cabinets and surrounding structures.

These interconnected layers of validation assures that PowerKeeper can maintain system integrity even under extreme conditions.

Validated Under Real Installation Constraints

Commercial and industrial sites often have limited installation space, requiring energy storage systems to be placed close to walls or adjacent to other cabinets. PowerKeeper enables seamless, space-efficient installation, adapting effortlessly to diverse and complex site conditions.The test simulates real-world installation scenarios, with clearances set at just 25 mm from walls and 450 mm between cabinets.

–     Unit-level test

The triggered battery cell reached a peak temperature of 595.2°C. Even under such extreme conditions, PowerKeeper demonstrated exceptional containment capability.

• No Impact on Adjacent Cabinets

Despite a unit spacing of only 450 mm, the neighboring unit recorded a maximum surface temperature of 13.7°C, far below the 141.3°C threshold defined by UL 9540A.

• Safe Operation with Minimal Wall Clearance

At a wall clearance of just 25 mm, the temperature rise on the wall surface was merely 29°C , significantly below the 97°C limit specified by the standard.

–     Module-Level: Precision Mitigation

In the module-level test, thermal runaway was intentionally triggered in three cells. The results were conclusive: no combustion, no explosion, and zero external debris or splashing. This confirms that any potential hazards are strictly contained within the PACK, even under triggered conditions.

–     Cell-Level: Control at the Source

The cell’s explosion-proof valve activated instantly, successfully releasing pressure and preventing any combustion or explosion, while capturing the precise thermal runaway trigger temperature of 216.3°C during cell-level testing.

These results confirm that PowerKeeper can safely operate even in space-constrained environments, effectively containing potential risks within tightly controlled boundaries.

From Passive Protection to Intelligent Safety

While UL 9540A certification validates PowerKeeper’s passive safety performance under extreme conditions, Sungrow has also integrated advanced active safety mechanisms to protect everyday operation.

Aligned with the PowerKeeper “7 Ups” safety concept, the system incorporates:

• 5D alerts (current, voltage, smoke, full-stack temperature monitoring, and water immersion detection)
• Triple-guard protection across cell, pack, and plant levels

Together, these features establish a comprehensive cell-to-plant safety architecture, enabling early risk detection, precise warning, and rapid intervention during daily operation.

Setting a New Safety Benchmark for C&I Energy Storage

The successful completion of cell-module-unit UL 9540A test for PowerKeeper not only provides authoritative validation of the system’s safety performance, but also marks a significant step forward in advancing system-level safety standards for the global C&I energy storage market.

As the demand for commercial and industrial energy storage accelerates worldwide, Sungrow remains committed to delivering safe, reliable, and intelligent energy solutions, empowering businesses to transition toward a more sustainable energy future with confidence.

About Sungrow

Sungrow, a global leader in renewable energy technology, has pioneered sustainable power solutions for over 29 years. As of Dec 2025, Sungrow has installed over 1000 GW of power electronic converters worldwide. The company is recognized as the world’s most bankable PV inverter and energy storage company (BloombergNEF). Its innovations power clean energy projects across the globe, supported by a network of 520 service outlets guaranteeing excellent customer experiences. At Sungrow, we’re committed to bridging to a sustainable future through cutting-edge technology and unparalleled service. For more information, please visit: www.sungrowpower.com/en

More than 3,100 exhibitors across battery, materials, equipment, and recycling segments, highlighting solid-state, sodium-ion, and carbon tracking

TIANJIN, China, April 7, 2026 /PRNewswire/ — China’s battery sector closed out 2025 with steady shipment volumes and climbing prices, a clear sign of improving quality and efficiency across the sector. Full-year exports totaled 37.896 billion battery units, roughly flat from a year earlier, but the value jumped 22.8% to $82.279 billion—underscoring the country’s continued edge in international markets. It is increasingly shifting toward power batteries and emerging energy storage technologies, with smart manufacturing playing a larger role in improving efficiency and supporting higher-value, lower-emission production. Riding that momentum, the 18^th China International Battery Fair (CIBF2026) is set to open on May 13–15 at the Shenzhen World Exhibition & Convention Center.

On the quality front, the industry has been shifting gears from sheer scale to more refined capability. In 2025, lithium-ion battery exports hit $76.746 billion, up 25.55% year on year. Higher-value lithium-ion products now account for a bigger slice of the export mix, climbing from 91.3% in 2024 to 93.3% in 2025. That shift in composition has become a key driver of overall export growth, reflecting a leaner product mix and a stronger competitive footing for Chinese battery makers in international markets. Going forward, the focus will be on breaking new ground in power batteries, energy storage, and solid-state technologies—filling gaps across the supply chain and speeding up the move from lab to production. This momentum provides an important context for CIBF2026.

As the competitiveness and market position of China’s battery sector continue to rise, CIBF2026 has become a leading international exhibition—one that sits at the crossroads of policy and industry, technology and market, and domestic and international opportunity.

This year’s event is on track to draw more than 3,100 exhibitors from around the world, with both scale and scope hitting new highs. The floor spans the supply chain—power and energy storage batteries, 3C cells, materials, manufacturing equipment, system solutions, and recycling applications—offering a broad look at where battery technology stands today. From solid-state and sodium-ion advances to intelligent equipment and carbon-tracking systems, the show will bring together key players across the international supply chain, giving companies a platform to showcase capabilities, connect with partners, and tap into new markets.

A lineup of high-level forums will run alongside the exhibition, including the CIBF2026 Conference on the Frontier Technology of Advanced Batteries, the Conference on Next-Generation Battery Technology and Advanced Manufacturing for Electric Aviation, the 6^th China International Conference on New Energy Storage Technology and Engineering Application, the Annual Conference of the CIAPS Lithium Iron Phosphate Materials Branch, and the 3rd International Battery Passport Conference. These sessions will dig into topics like emerging storage technologies and battery carbon-footprint management, bringing together industry participants to explore practical paths forward. More than 2,000 experts, researchers, and business leaders are expected to attend, offering a read on policy direction, emerging tech, and market trends.

This year’s show will also put a spotlight on energy storage batteries, fuel cells, recycling technologies, and energy-efficient manufacturing equipment—positioned as a platform for zero-carbon industrial parks and low-emission development initiatives. The goal is to back the kind of robust growth that comes with a low-carbon economy.

With the global energy transition accelerating and China’s battery sector gaining strength, visitor registration for CIBF is now open. Industry professionals can reserve their spot through the official platform to take in what’s become a key gathering point for the international battery community.

For more information, visit: https://www.cibf.org.cn/en-US.

–    Featuring leading contemporary artists including Kiki Smith, Rose Wylie, Carol Bove, Gala Porras-Kim, and Alvaro Barrington
–    An overview of the diverse visual languages of contemporary art through approximately 80 works spanning painting, photography, sculpture, and installation

SEOUL, South Korea, April 7, 2026 /PRNewswire/ — Amorepacific Museum of Art (Director Seungchang Jeon) presents a special exhibition of contemporary art from its collection, APMA, CHAPTER FIVE – FROM THE APMA COLLECTION. Featuring works by over 40 Korean and international artists—including Kiki Smith, Rose Wylie, Carol Bove, Gala Porras-Kim, Nam June Paik, Lee Bul, Haegue Yang, and Lee Ufan—the exhibition will be on view from April 1 to August 2.

The exhibition brings together works by globally acclaimed artists who have recently garnered attention, alongside representative pieces by leading figures of contemporary art. Featured artists include Kiki Smith, whose practice explores themes of life and death, femininity, and the relationships between myth and nature; British artist Rose Wylie, who reconfigures the language of painting through everyday imagery; Carol Bove, who expands the structural and material possibilities of sculpture using industrial materials; and Gala Porras-Kim, whose work examines layers of time embedded in objects and places beyond human-centered narratives. The exhibition also presents works by David Hockney and Donald Judd.

The exhibition also introduces works by leading figures in Korean contemporary art. Highlights include Kon-Tiki, a monumental installation by Nam June Paik that established video art as an independent genre, as well as TV Vertical Flower, a large-scale work being unveiled in a museum for the first time in over 20 years. Also on view are Stacked Corners – Ventilated Square of Orange and Blue, a new work by Haegue Yang, who has continued her conceptual installation practice based in Berlin and Seoul, and The Secret Sharer, a seminal work by Lee Bul, a major figure in Korean contemporary art known for revealing the anxieties and fractures of modern civilization.

Comprising approximately 80 works across painting, photography, sculpture, and installation, the exhibition surveys the diverse visual languages of contemporary art shaped within different cultural and historical contexts. It examines artistic experimentation amid shifts in contemporary art while also tracing the development and transformation of Korean contemporary art from Dansaekhwa to recent expansions into diversified media and themes.

In conjunction with the exhibition, Amorepacific Museum of Art will offer programs designed to deepen engagement with the collection, from With Curator, guided tours led by curators, to With Curator Professional, an advanced program for in-depth exploration.

EXHIBITION OVERVIEW

• Title: APMA, CHAPTER FIVE – FROM THE APMA COLLECTION
• Dates: April 1 (WED) through August 2 (SUN), 2026
• Opening Hours: 10 AM to 6 PM (Closed on Mondays)
• Venue: Amorepacific Museum of Art (100, Hangang-daero, Yongsan-gu, Seoul, South Korea)
• Admission Information: APMA website: http://apma.amorepacific.com

– Presented key product lines spanning aesthetic, wound care, bone and spine, and surgical fields
– Signed supply agreements totaling KRW 5.3 billion with partners from Singapore, Malaysia, Pakistan, Taiwan, and the Philippines

SEOUL, South Korea, April 7, 2026 /PRNewswire/ — CGBIO (CEO Hyunseung Yu), a biotechnology company specializing in regenerative medicine, announced on the 6th that it participated in the 41st Korea International Medical & Hospital Equipment Show (KIMES 2026), recently held at COEX in Seoul, where it showcased products across aesthetic, wound care, bone and spine, and surgical fields, and signed overseas supply contracts worth a total of KRW 5.3 billion with partners from five countries.

KIMES is a leading medical device and hospital equipment exhibition that brings together healthcare professionals, industry stakeholders, and domestic and international buyers to explore the latest medical technologies and market trends. At this year’s exhibition, CGBIO focused not only on introducing individual products but also on presenting its integrated solution competitiveness by connecting its core product portfolio.

At the forefront of the exhibition were key products including FACETEM (aesthetic), Curasys ME (wound care), NOVOSIS (bone substitute), and CG GEL (endoscopic hemostatic agent).

FACETEM is a collagen stimulator that goes beyond a conventional filler by inducing collagen production within the body, addressing the global aesthetic market’s growing emphasis on natural volume enhancement and skin regeneration. Curasys ME is a next-generation negative pressure wound therapy (NPWT) device designed with both medical professionals and patient convenience in mind, offering a more efficient wound care environment. NOVOSIS, known for its superior osteoinductive performance, represents CGBIO’s technological competitiveness in the bone and spine segment. CG GEL, an endoscopic hemostatic agent, demonstrated its applicability in surgical and procedural settings by effectively controlling bleeding during endoscopic interventions.

In addition, CGBIO exhibited a wide range of products across various segments, including AILEENE, GISELLELIGNE, LUXX, DOOTH, Curasys2, CuraVAC Double Channel, BELUNA, NOVOMAX, Verteon, EXCENDER, CUVIS-Spine, Solendos Endo Tower, Realist Bone Model, ARISTENT, and NOVONIX.

During the exhibition, CGBIO strengthened its foundation for global market expansion by proposing tailored strategies that reflect country-specific healthcare environments and partner needs. Through on-site consultations, the company expanded engagement with overseas buyers by explaining the clinical value and applicability of each product line.

Contract signing ceremonies with overseas partners were also held during the exhibition period. CGBIO signed exclusive supply agreements with Neuva Era for FACETEM in Singapore and Malaysia, and with MediNova Healthcare for exclusive distribution of FACETEM in Pakistan. Additionally, the company entered into a supply agreement with HCT Regenerative Co., Ltd. for CGDerm One-Step in Taiwan, and with Variance Trading Corporation for wound care solution products including Curasys, CuraVAC, EasyFoam, and Easydew MD Cream in the Philippines.

Hyunseung Yu, CEO of CGBIO, stated, “KIMES 2026 served as an opportunity for CGBIO to demonstrate its competitiveness as a comprehensive medical device solution provider, moving beyond a single-product focus.” He added, “We will continue to expand our overseas business foundation through strategic product proposals and partnerships tailored to the needs of each market and partner.”

• Hyundai Motor initiates global naming of sea forests across Korea, Argentina and Australia
• Campaign highlights the climate value of marine ecosystems through naming and identity-building during Earth Month
• Dedicated website and mapping registrations aim to build global awareness and data access
• Ongoing marine conservation includes Ulsan sea forest restoration projects conducted in partnership with Korean government agencies

SEOUL, South Korea , April 7, 2026 /PRNewswire/ — Hyundai Motor Company today announced the global launch of its ‘Forests Without Names’ campaign, an initiative that celebrates Earth Month this April by naming sea forests worldwide while highlighting their environmental importance.

The campaign aims to increase awareness of these often overlooked underwater ecosystems and reinforce Hyundai Motor’s long-term marine conservation efforts, including seaweed-based sea forest restoration off the coast of Ulsan, South Korea, and marine waste cleanup projects spanning 10 countries.

“Hyundai Motor Company has been committed to forest conservation across both terrestrial and marine ecosystems. Through the ‘Forests Without Names’ campaign, we are pleased to shed light on sea forests and highlight their ecological value and the importance of protecting our marine environments. We are especially proud to bring this story to life creatively — sparking curiosity about what has long gone unnoticed, and inspiring people to care about what they now know by name. We will continue to advance our sustainability efforts in pursuit of a more environmentally responsible future.”
 – Hyunchul Jeon, Head of Future Business & Sustainability Group at Hyundai Motor Company

What Are Sea Forests and Why Do They Matter?

Sea forests are underwater ecosystems formed by dense marine algae such as kelp and seaweed. Like terrestrial forests, they provide habitats, filter marine pollutants and support coastal biodiversity.

Global scientific and policy interest in seaweed’s climate value increased in 2025, as discussions at the IPCC’s 63rd Session in Lima highlighted the need to explore methodological pathways for including seaweed in future carbon accounting frameworks.

Why Is Hyundai Naming Sea Forests?

Unlike iconic terrestrial forests, many sea forests have no formal names — anonymity that limits their visibility and the protection they receive. The campaign addresses this fundamental gap by giving these ecosystems clear identities.

Finalized names will be added to the campaign’s Sea Forest Map, which Hyundai Motor ultimately aims to integrate with widely used global mapping platforms and leading Korean platforms including Kakao Map. Hyundai Motor brings the public directly into the process through open voting — driving a shift in environmental communication from awareness alone toward recognition, documentation and long-term protection.

How Does the ‘Forests Without Names’ Campaign Work?

The campaign builds on Hyundai Motor’s earlier environmental storytelling initiatives, including the Cannes Lions-winning ‘Tree Correspondents’ campaign in 2025, which used artificial intelligence (AI) to give trees a voice and spotlight the importance of forest conservation.

This new initiative expands Hyundai Motor’s sustainability focus from land ecosystems to marine environments through three main actions:

• Naming three sea forests worldwide:
• • Korea: One of the two restored sea forests in Ulsan is officially named “Ullim” — a Korean word evoking resonance or an echo — through a formal naming process conducted in close collaboration with the Ministry of Oceans and Fisheries and the Korea Fisheries Resources Agency (FIRA).
  • Argentina: Hyundai has designated an official sea forest name “Auken Aiken” meaning “Field of Life” in the local indigenous language through a partnership with a local NGO specialized in marine conservation and community groups.
  • Australia: The final name will be determined through a public voting process conducted via Hyundai Motor’s global social channels and campaign website, with shortlisted candidates selected jointly with local NGOs and community groups.
• Registering these sites on a dedicated campaign website and mapping platform such as ‘Kakao Map’, with the ambition to expand to global platforms
• Working closely with the Korean government, NGOs and local communities to ensure scientific credibility and long-term conservation outcomes

The dedicated campaign website will evolve into a global Sea Forest Data Hub, archiving verified information such as location, ecosystem characteristics, and restoration activities. By making this data publicly accessible, Hyundai aims to build one of the world’s most comprehensive open databases on underwater forests.

What Will Happen During Earth Month?

Key milestones include:

• April 3
  • Release of teaser campaign video and open campaign website
  • Announcement of sea forest names in Korea and Argentina, alongside public voting in Australia
• April 22 (Earth Day): Release of main campaign film and announcement of Australia’s final sea forest name

Finalized names will be added to the campaign’s Sea Forest Map, with the goal of registering these sea forests on global mapping platforms in the future.

How Does This Connect to Hyundai Motor’s Broader Marine Conservation Work?

The naming initiative is part of Hyundai Motor’s longer-term environmental strategy rather than a standalone campaign.

Hyundai Motor has been restoring seaweed forests in Ulsan since 2024 under agreements with Korea’s Ministry of Oceans and Fisheries, the Korea Fisheries Resources Agency and Ulsan Metropolitan City. The project spans approximately 3.96 square kilometers and is expected to offset about 1,300 tons of CO₂ annually through carbon absorption and ecosystem restoration, through methods including seaweed transplantation, spore dispersal, artificial underwater longline installations, local species reproduction support and seabed cleanup.

Meanwhile, since 2021, the company has conducted marine waste collection projects in partnership with the Healthy Seas foundation across Europe, Korea and the United States. These efforts have resulted in the removal of approximately 320 tons of marine debris, including discarded fishing nets later recycled into ECONYL^® nylon fiber used in vehicle materials such as floor mats for IONIQ 5, IONIQ 6, IONIQ 9, INSTER, SANTA FE and NEXO models sold in Europe.

Hyundai Motor aims to support ecosystem recovery and realize potential climate mitigation benefits through these initiatives.

About Hyundai Motor Company

Established in 1967, Hyundai Motor Company is present in over 200 countries with more than 120,000 employees dedicated to tackling real-world mobility challenges around the globe. Based on the brand vision ‘Progress for Humanity,’ Hyundai Motor is accelerating its transformation into a Smart Mobility Solution Provider. The company invests in advanced technologies such as robotics and Advanced Air Mobility (AAM) to bring about revolutionary mobility solutions while pursuing open innovation to introduce future mobility services. In pursuit of a sustainable future for the world, Hyundai will continue its efforts to introduce zero-emission vehicles with industry-leading hydrogen fuel cell and EV technologies.

More information about Hyundai Motor and its products can be found at:
https://www.hyundai.com/worldwide/en/ or Newsroom: Media Hub by Hyundai

Follow our Hyundai Global Newsroom Instagram channel @hyundai media hub

Visit the Hyundai Media Hub for more content

TAIPEI, April 7, 2026 /PRNewswire/ — In a robust nod to sustainability innovation, Hon Hai Technology Group (“Foxconn”) (TWSE:2317) has honored 152 teams and projects at the “2026 Hon Hai-Foxconn Sustainability Awards”, an in-house distinction that accelerates the work of the world’s largest electronics manufacturer and leading technology solutions provider to innovate for the good.

Recognizing environmental, social and governance, across Asia, Americas and Europe, the scale and impact of the Sustainability Awards continue to grow, attracting 1,504 entries from Foxconn teams in its third year – five times more than its inaugural edition. Nitrogen safety in Vietnam, zero-carbon cleaning in China and exoskeleton-assisted equipment in the Czech Republic were among projects celebrated, demonstrating deepening of ESG capabilities.

“Through the Sustainability Awards platform, Foxconn colleagues around the world can share outcomes of ESG initiatives. This also encourages all units to transform innovative practices into tangible results, making sustainability not just a goal, but a part of daily operations,” said Foxconn Chairman Young Liu. The awards ceremony this year was held at the Shenzhen campus, a World Economic Forum-designated Lighthouse factory site.

Nearly 500 colleagues and supply-chain partners from the Group’s operations worldwide attended, in person and online. This year’s event recognized innovative achievements of the Group’s supply chain, such as at STMicroelectronics, Murata Manufacturing Co and Winbond Electronics Corp, while engaging in a summit roundtable to hear their views about Foxconn’s sustainability development.

Winners showcased diverse innovations:

• Czech Republic: Introduction of exoskeleton-assisted equipment to improve working posture and reduce occupational injury risks, which earned its own recognition in the Czech Republic this year.
• US: Amid operational expansion in the key market, US operations integrated management processes through digital platforms to enhance operational efficiency and governance transparency.
• India: Water-saving advocacy, rainwater harvesting and wastewater reuse recognized in comprehensive program for improved water-use efficiency.
• Vietnam: Improved cost control through nitrogen safety optimization.
• China: Reduction in electricity costs and carbon emissions through zero-carbon cleaning improvements.

The selection process included document review, jury panel discussions and external evaluation, spanning three rounds and involving up to 100 judges. External experts, scholars, and professional organizations joined in-house judges this year. Following more than two months of evaluation, 332 entries were shortlisted based on different ESG domains and categories.

About Foxconn here.

MELBOURNE, Australia and INDIANAPOLIS, April 7, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides a market update on its commercial and operational performance for the quarter ended March 31, 2026 (Q1 2026).

Q1 2026 Highlights

• Q1 2026 unaudited Group revenue of US$230 million, up 11% quarter-over-quarter.

• FY 2026 revenue guidance of US$950 million to US$970 million is reaffirmed.

• Precision Medicine Q1 2026 unaudited revenue of US$186 million, up 16% quarter-over-quarter. Strong revenue growth in both Illuccix® and Gozellix® segments.

• ProstACT® Global Phase 3 study of TLX591-Tx prostate cancer therapy candidate: Part 1 lead-in met safety and dosimetry objectives, with no new safety signals observed^[1].

• TLX101-Px (brain cancer imaging candidate): New Drug Application (NDA) resubmitted to the United States (U.S.) Food and Drug Administration (FDA)^[2] for Pixclara®^[3]. Marketing Authorization Application (MAA) filed in Europe^[4] for Pixlumi®³.

• TLX591-Px^[5]: NDA accepted in China by the National Medical Products Administration (NMPA)^[6].

Q1 2026 Revenue (Unaudited)

Executive Commentary

Dr. Christian Behrenbruch, Managing Director and Group CEO, stated, “Growth accelerated across our Precision Medicine business in the first quarter, with U.S. dose volumes increasing 5% quarter-over-quarter. This performance reflects the growing uptake of Gozellix alongside Illuccix, contributing to market share gains underpinned by disciplined sales execution and pricing, and high-quality service delivery despite extreme North American weather conditions, an advantage of the pharmacy distribution model. With our two‑product PSMA^[9] imaging strategy, differentiated clinical positioning and expanding commercial presence globally, we are seeing a solid foundation for continued growth through 2026. Importantly, we are delivering on our strategic priorities to advance our high-value clinical programs, demonstrated by the momentum in our therapeutics pipeline this quarter.”

Therapeutics Business Unit

Telix continues to progress its industry-leading Therapeutics pipeline, which spans multiple product candidates and disease areas. Q1 2026 highlights include:

• TLX591-Tx (lutetium (¹⁷⁷Lu) rosopatamab tetraxetan): Part 1 of ProstACT Global, the Phase 3 trial of its lead prostate cancer therapy candidate, achieved its study objectives, demonstrating an acceptable safety and tolerability profile with no new safety signals observed¹. No adverse drug-drug interactions were observed in TLX591-Tx combinations, demonstrating the feasibility of integrating TLX591-Tx with current standard of care therapies for mCRPC^[10], including ARPIs^[11] (enzalutamide or abiraterone) and docetaxel. Telix has commenced engagement with the FDA to present data from Part 1 and ascertain eligibility for U.S. patients to participate in Part 2 (randomized treatment expansion). Part 2 is open for enrollment in Australia, New Zealand and Canada, with site activation underway in preparation to open enrollment in China, Singapore, South Korea, Türkiye, the United Kingdom and Japan, where regulatory approvals have already been granted.

• TLX250-Tx (lutetium (¹⁷⁷Lu) girentuximab tetraxetan): Telix has opened its first clinical site and is recruiting patients for Part 1 of LUTEON^[12], a pivotal trial of TLX250-Tx as a monotherapy in advanced ccRCC^[13]. Trial recruitment will initially focus ex-U.S.

• TLX101-Tx (¹³¹I-iodofalan): Telix has enrolled the first patient in IPAX-BrIGHT, an international, multi-center pivotal trial of TLX101-Tx in patients with recurrent glioblastoma^[14]. The trial is now open for enrollment in Australia, Austria and the Netherlands and has received regulatory approval to commence in Belgium.

• TLX090-Tx (¹⁵³Sm-DOTMP): Telix continues to dose patients in SOLACE^[15], a Phase 1 study of a drug candidate for treating pain in patients with osteoblastic bone metastases from prostate and breast cancers. The study was expanded this quarter to include additional U.S. sites to accelerate recruitment. 

• TLX597-Tx (¹⁷⁷Lu-DOTA-HYNIC-panPSMA): TLX597-Tx is a “next generation” PSMA-targeting prostate cancer therapy candidate being developed to facilitate patient access in select geographies, where routine clinical availability to approved therapies is limited or not available. Early clinical data suggests a favorable asset biodistribution with limited uptake in healthy organs of concern (e.g., salivary glands, kidneys) relative to available ¹⁷⁷Lu-PSMA therapies. Interim data from OPTIMAL-PSMA^[16], an investigator-led, randomized, dose intensification study of TLX597-Tx in mCRPC, will be presented at the International Prostate Cancer Symposium in April 2026. 

Precision Medicine Business Unit

PSMA imaging portfolio:

• Telix continues to expand its commercial footprint with Illuccix now launched in 21 countries globally, which includes 16 countries in Europe. This growing international presence enhances access to PSMA-PET/CT imaging^[17] while establishing a scalable commercial and operational platform to support future product launches, including follow-on therapeutic products.

• Telix’s broad proposed label for TLX591-Px (Illuccix) is under review by the NMPA Centre for Drug Evaluation as part of the NDA submission^[18].

TLX101-Px, (Floretyrosine F 18 or ¹⁸F-FET):

• Telix has resubmitted its NDA in the U.S. with the additional clinical data and analysis as agreed with the FDA.

• Telix has submitted a MAA in Europe covering commercially significant markets, seeking to expand patient access to advanced brain imaging.

Zircaix®³ (TLX250-Px, ⁸⁹Zr-DFO-girentuximab):

• Based on two successful Type A meetings with the FDA, Telix believes it has aligned on key outstanding issues for the Biologics License Application (BLA) resubmission, including demonstration of drug product comparability between clinical trial material and scale-up commercial production. The Company is now completing the agreed deliverables and documentation required, targeting a H1 2026 submission.

Corporate Updates

Telix has announced the appointment of David Gill as Non-Executive Director (NED), effective May 11, 2026, as part of its Board renewal process^[19]. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as NED. The Board believes Mr. Gill’s appointment will enhance the Board’s capability, with extensive experience in U.S. public company governance, financial oversight and senior leadership across commercial and clinical-stage biopharmaceutical companies.

FY 2026 guidance

• Telix reaffirms FY 2026 revenue guidance of US$950 million to US$970 million^[20].

• Guidance reflects revenue from product sales in jurisdictions with a marketing authorization, and a full year of revenue contribution from RLS.

• Telix reaffirms research and development (R&D) expenditure guidance of US$200 million to US$240 million, subject to achieving ongoing global commercial milestones.

About Telix Pharmaceuticals Limited

Telix is a global biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland), and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).

Illuccix (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the FDA^[21], and in multiple markets globally. Gozellix (kit for the preparation of gallium-68 (⁶⁸Ga) gozetotide injection) has been approved by the FDA^[22]. No other Telix product mentioned in this announcement has received a marketing authorization in any jurisdiction.

Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.

This announcement has been authorized for release by the Telix Pharmaceuticals Limited Disclosure Committee on behalf of the Board.

Guidance Disclaimer

The stated revenue guidance is based on expected global and domestic economic conditions and is subject to known and unknown risks, uncertainties and other factors that may cause our actual results to differ materially. As such, investors are cautioned not to place undue reliance on this guidance and in particular Telix cannot guarantee a particular result. In compiling financial forecasts, a number of key variables that may have a significant impact on guidance have been identified and are listed below.

Key variables that could cause actual results to differ materially include: the success and timing of research and development activities; decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation, regulation, or policy that affects product production, distribution, pricing, reimbursement, access or tax; acquisitions and divestitures; research collaborations; litigation or government investigations; and Telix’s ability to protect its patents and other intellectual property. See the Legal Notices section below for additional information, risks and assumptions.

Legal Notices

Cautionary Statement Regarding Forward-Looking Statements. 

You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.

The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.

This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.

Trademarks and Trade Names. All trademarks and trade names referenced in this press release are the property of Telix Pharmaceuticals Limited (Telix) or, where applicable, the property of their respective owners. For convenience, trademarks and trade names may appear without the ® or ™ symbols. Such omissions are not intended to indicate any waiver of rights by Telix or the respective owners. Trademark registration status may vary from country to country. Telix does not intend the use or display of any third-party trademarks or trade names to imply any affiliation with, endorsement by, or sponsorship from those third parties.

©2026 Telix Pharmaceuticals Limited. All rights reserved.